XRCC1‐mediated DNA repair is associated with progression‐free survival of multiple myeloma patients after autologous stem cell transplant-Reference-Cited by-同舟云学术

XRCC1‐mediated DNA repair is associated with progression‐free survival of multiple myeloma patients after autologous stem cell transplant

Published:2019-09-22 Issue:12 Volume:58 Page:2327-2339
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Mol Carcinog

Author:

Persaud Avinash K.¹,Li Junan²³^ORCID,Johnson Jasmine A.²,Seligson Nathan⁴,Sborov Douglas W.⁵,Duah Ernest²,Cho Yu Kyoung¹,Wang Danxin⁶,Phelps Mitch A.¹³,Hofmeister Craig C.⁷,Poi Ming J.¹²⁴^ORCID

Affiliation:

1. Division of Pharmaceutics and Pharmaceutical Chemistry, College of PharmacyThe Ohio State University Columbus Ohio

2. Division of Pharmacy Practice and Science, College of PharmacyThe Ohio State University Columbus Ohio

3. Comprehensive Cancer CenterThe Ohio State University Columbus Ohio

4. Department of PharmacyThe Ohio State University Wexner Medical Center Columbus Ohio

5. Division of Hematology and Hematologic MalignanciesUniversity of Utah—Huntsman Cancer Institute Salt Lake City Utah

6. Department of Pharmacotherapy and Translational Research, College of PharmacyUniversity of Florida Gainesville Florida

7. Department of Hematology and OncologyWinship Cancer Institute of Emory University Atlanta Georgia

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mc.23121

Reference51 articles.

1. Cancer statistics, 2019

2. Not too little, not too much—just right! (Better ways to give high dose melphalan)

3. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

4. High-dose intravenous melphalan: a review.

5. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. <i>PARP1</i> and <i>POLD2</i> as prognostic biomarkers for multiple myeloma in autologous stem cell transplant;Haematologica;2023-03-02

2. Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant;Cancer Genomics - Proteomics;2022-12-29

3. A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy;Anticancer Research;2021-12-29

4. Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy;International Journal of Molecular Sciences;2021-09-27

5. A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes;Cancer Chemotherapy and Pharmacology;2021-08-04